Eupraxia announces first patient dosed in phase I clinical trial of EP-104IAR to treat osteoarthritis-related pain
VICTORIA, BC – Eupraxia, an emerging pharmaceutical company focused on optimizing drug delivery, announced today the initiation of STEP UP – a phase I study of its lead investigational product (EP-104IAR), for the treatment of pain associated with osteoarthritis (OA) of the knee. EP-104IAR is an...